Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 73-83

  Villa, Giorgio La ^a   Laffi, Giacomo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Atrial volume; Cirrhosis; Homeostasis; Natriuretic peptides (NPs); Signal sequence

Indexed keywords

EID: 84889483994     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch6     Document Type: Chapter

References (89)

1. Brenner BM, Ballermann BJ, Gunning ME et al. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70:665-99.
2. Lang CC, Choy AMJ, Struthers AD. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992; 83:519-27.
3. Suga S, Nakao K, Hosoda K et al. Natriuretic peptides. N Engl J Med 1998; 339:321-8.
4. Beltowski J, Wojcicka G. Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit 2002; 8:RA39-52
5. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-22.
6. Forssmann WG, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2002; 51:450-62.
7. Schirger JA, Heublein DM, Chen HH et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999; 74: 126-30.
8. Richards AM, Lainchbury JG, Nicholls MG et al. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 2002; 359:5-6.
9. Weist R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35:478-91.
10. Kirstetter P, Moreau R, Vachiery F et al. Plasma concentrations of cyclic 3',5'-guanosine monophosphate in patients with cirrhosis with atrial natriuretic peptide and haemodynamics. J Gastroenterol Hepatol 1997; 12:233-36.
11. Cohen D, Kok GY, Nikonova LN et al. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996; 271:9863-9.
12. Melo LG, Steinhelper ME, Pang SC et al. ANP in the regulation of arterial pressure and fl uid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics 2000; 3:45-58.
13. La Villa G, Stefani L, Lazzeri C et al. Acute effects of physiological increments of brain natriuretic peptide in man. Hypertension 1995; 26:628-33.
14. La Villa G, Fronzaroli C, Lazzeri C et al. Cardiovascular and renal effects of low-dose brain natriuretic peptide in man. J Clin Endocrinol Metab 1994; 78:1166-71.
15. Tamura N, Ogawa Y, Chusho H et al. Cardiac fi brosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97:4239-44.
16. Lopez MJ, Garbers DL, Kuhn M. The guanylyl cyclasedefi cient mouse defi nes differential pathways of natriuretic peptide signalling. J Biol Chem 1997; 273:23064-8.
17. Barletta G, Lazzeri C, Vecchiarino S et al. Low-dose Ctype natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 1998; 31:802-8.
18. Chusho H, Tamura N, Ogawa Y et al. Dwarfi sm and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001; 98:4016-21.
19. Epstein M. Natriuretic hormone and the sodium retention in cirrhosis. Gastroenterology 1981; 81:395-9.
20. Fernández-Cruz A, Marco J, Cuadrado LM et al. Plasma levels of atrial natriuretic peptide in cirrhotic patients. Lancet 1985; ii:1439-40.
21. Morgan TR, Imada T, Holister AS et al. Plasma human natriuretic factor in cirrhosis and ascites with and without functional renal failure. Gastroenterology 1988; 95:1641-7.
22. Ginès P, Jiménez W, Arroyo V et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988; 8:636-42.
23. Campbell PJ, Skorecki KL, Logan AG et al. Acute effects of peritoneovenous shunting on plasma atrial natriuretic peptide in cirrhotic patients with massive refractory ascites. Am J Med 1988; 84:112-19.
24. Rector WG Jr, Adair O, Hossack KF et al. Atrial volume in cirrhosis: relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology 1990; 99:766-70.
25. Salerno F, Badalamenti S, Moser P et al. Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of largevolume paracentesis. Gastroenterology 1990; 98:1063-70.
26. La Villa G, Romanelli RG, Casini Raggi V et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992; 16:156-61.
27. Angeli P, Caregaro L, Menon F et al. Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: pathophysiological and clinical implications. Hepatology 1992; 16:1389-94.
28. Fernández-Rodriguez C, Prieto J, Quiroga J et al. Atrial natriuretic factor in cirrhosis: relationship to renal function and hemodynamic changes. J Hepatol 1994; 21:211-16.
29. Bernardi M, Fornalè L, Di Marco C et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995; 22:309-18.
30. Bernardi M, Di Marco C, Trevisani F et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steadystate conditions and after postural changes. Hepatology 1992; 16:341-6.
31. Trevisani F, Colantoni A, Sica G et al. High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: indirect evidence of reduced natriuretic effectiveness of the peptide. Hepatology 1995; 22:132-7.
32. Wong F, Liu P, Allidina Y et al. Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. Gastroenterology 1995; 108:1820-7.
33. Iwao T, Oho K, Nakano R et al. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosyne monophosphate production in preascitic cirrhosis. J Hepatol 2000; 32:426-33.
34. Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32 (suppl. 1): 157-70.
35. Warner LC, Campbell PJ, Morali GA et al. The response of atrial natriuretic factor and sodium excretion to dietary sodium challenges in patients with chronic liver disease. Hepatology 1990; 12:460-6.
36. Tesar V, Horky K, Petryl J et al. Atrial natriuretic factor in liver cirrhosis-the infl uence of volume expansion. Horm Metabol Res 1989; 21:519-22.
37. La Villa G, Salmerón JM, Arroyo V et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992; 102:2114-19.
38. Epstein M, Loutzenhiser R, Norsk P et al. Relationship between plasma ANF responsiveness and renal sodium handling in cirrhotic humans. Am J Nephrol 1989; 9:133-43.
39. Skorecki KL, Leung WM, Campbell PJ et al. Role of atrial natriuretic peptide in the natriuretic response to central volume expansion induced by head-out water immersion in sodium-retaining cirrhotic subjects. Am J Med 1988; 55: 375-82.
40. Legault L, Warner LC, Leung WM et al. Assessment of atrial natriuretic peptide resistance in cirrhosis with head-out water immersion and atrial natriuretic peptide infusion. Can J Physiol Pharmacol 1993; 71:157-64.
41. Klepetko W, Muller Ch, Hartter E et al. Plasma atrial natriuretic factor in cirrhotic patients with ascites. Effect of peritoneovenous shunt implantation. Gastroenterology 1988; 95:764-70.
42. Moreau R, Hadegue A, Pussard E et al. Relationship between plasma atrial natriuretic peptide concentrations and hemodynamics and hematocrit in patients with cirrhosis. Hepatology 1991; 14:1035-9.
43. Henriksen JH, Bendtsen F, Sorensen TI et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97:1506-13.
44. Hartleb M, Rudzki K. Segmental mean transit time of 99mtechnetium within central vascular space in liver cirrhosis. Liver 1992; 12:191-8.
45. Laffi G, Barletta G, La Villa G et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113:891-8.
46. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87:9-15.
47. Poulos JE, Gower WR, Fontanet HL et al. Cirrhosis with ascites: increased atrial natriuretic peptide messenger RNA expression in rat ventricle. Gastroenterology 1995; 108: 1496-1503.
48. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001; 101:621-8.
49. Wong F, Blendis L. Pathophysiology of sodium retention and ascites formation in cirrhosis: role for atrial natriuretic factor. Semin Liver Dis 1994; 14:59-70.
50. Salerno F, Badalamenti S, Incerti P et al. Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. Hepatology 1988; 8:21-6.
51. Laffi G, Pinzani M, Meacci E et al. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology 1989; 96:167-77.
52. Ginès P, Titó L, Arroyo V et al. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology 1992; 102:280-6.
53. Warner L, Skorecki K, Blendis LM et al. Atrial natriuretic factor and liver disease. Hepatology 1993; 17:500-13.
54. Jiménez W, Gutkowska J, Ginès P et al. Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. Hepatology 1991; 14:601-7.
55. Angeli P, Jiménez W, Veggian R et al. Increased activity of guanosyne 3'-5'-cyclic monophosphate phosphodiesterase in renal tissue of cirrhotic rats with ascites. Hepatology 2000; 31:304-10.
56. Gerbes AL, Wernze H, Arendt RM et al. Atrial natriuretic factor and rennin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989; 9:417-22.
57. Morali GA, Floras JS, Legault L et al. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. Am J Med 1991; 91:383-92.
58. Koepke JP, Jones S, DiBona GF. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987; 252:R1019-R1023.
59. Abraham WT, Lauwaards ME, Peña RL et al. Reversal of atrial natriuretic peptide resistance by increasing distal tubular sodium delivery in patients with decompensated cirrhosis. Hepatology 1995; 22:737-43.
60. Wong F, Liu P, Blendis L. Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut 2001; 49:847-51.
61. Dussaule JC, Grangè JD, Wolf JP et al. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 1991; 72:653-9.
62. Angeli P, Jiménez W, Arroyo V et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20:948-54.
63. La Villa G, Lazzeri C, Pascale A et al. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis. Am J Gastroenterol 1997; 92:852-7.
64. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 5:1151-7.
65. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites and renal sodium retention in cirrhosis: the overfl ow theory of ascites formation. Ann NY Acad Sci 1970; 170:202-12.
66. Vesely L, Preston R, Winters CJ et al. Increased release of the N-terminal and C-terminal portions of the atrial natriuretic factor prohormone during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol 1991; 11: 207-16.
67. Vesely DL, Preston R, Gower WR Jr et al. Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol 1996; 16: 128-37.
68. Salò J, Jiménez W, Kuhn M et al. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology 1996; 24: 1428-32.
69. Carstens J, Greines J, Jensen KT et al. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol 1998; 9:1489-98.
70. Henriksen JH, Getze JP, Fuglsang S et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relationship to cardiovascular dysfunction and severity of disease. Gut 2003; 52:1511-17.
71. La Villa G, Riccardi D, Lazzeri C et al. Blunted natriuretic response to low dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites. Hepatology 1995; 22:1745-50.
72. Gülberg V, Møller S, Henriksen JH et al. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000; 47: 852-7.
73. Henriksen JH, Gulberg V, Gerbes AL et al. Increased arterial compliance in cirrhosis is related to decreased arterial Ctype natriuretic peptide, but not to atrial natriuretic peptide. Scand J Gastroenterol 2003; 38:559-64.
74. Komeichi H, Moreau R, Cailmail S et al. Blunted natriuresis and abnormal systemic hemodynamic responses to Ctype and brain natriuretic peptides in rats with cirrhosis. J Hepatol 1995; 22:319-25.
75. Moreau R, Tazi KA, Komeichi H et al. Haemodynamic responses to a ring-deleted analogue of atrial natriuretic peptide in rats with cirrhosis. Liver 2000; 20:88-92.
76. Fábrega E, Crespo J, Rivero M et al. Dendroapis natriuretic peptide in hepatic cirrhosis. Am J Gastroenterol 2001; 96:2724-9.
77. De Wardener HE, Mills IH, Clapman WF et al. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci 1961; 21:249-58.
78. De Wardener HE, Clarkson EM. Concept of natriuretic hormone. Physiol Rev 1985; 65:658-759.
79. Goto A, Yamada K, Yagi N et al. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992; 44:377-99.
80. De Wardener HE. The hypothalamus and hypertension. Physiol Rev 2001; 81:1599-658.
81. Ferrandi M, Manunta P. Ouabain-like factor: is this the natriuretic hormone? Curr Opin Nephrol Hypertens 2000; 9:165-71.
82. Hamlyn JM, Blaustein MP, Bova S et al. Identifi cation and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88:6259-63.
83. Kramer HJ. Natriuretic hormone: its possible role in fl uid and electrolyte disturbances in chronic liver disease. Postgrad Med J 1975; 51:532-40.
84. Wilkinson SP, Moodie H, Alam A et al. Renal retention of sodium in cirrhosis and fulminant hepatic failure. Postgrad Med J 1975; 51:527-31.
85. Naccarato R, Messa P, D'Angelo A et al. Renal handling of sodium and water in early chronic liver disease. Gastroenterology 1981; 81:205-10.
86. Nanji AA, Greenway DC. Correlation between serum albumin and digoxin-like immunoreactive substance in liver disease. J Clin Pharmacol 1986; 26:152-3.
87. Yang SS, Korula J, Sundheimer JE et al. Digoxin-like immunoreactive substance in chronic liver disease. Hepatology 1986; 9:363-6.
88. La Villa G, Asbert M, Jimenez W et al. Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology 1990; 12:467-75.
89. Asbert M, Clària J, Jiménez W et al. Blunted natriuretic response to human urine extracts with Na+, K+-ATPase inhibiting activity in experimental cirrhosis. J Hepatol 1994; 20:660-5.